Arca
Skip to content
Tools
Tools

ITGA4, ITGB1: Integrin alpha-4/beta-1

Complex in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on ITGA4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Antibody 1

Approved1

  • Natalizumab

Phase 30

    Phase 21

    • Firategrast

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      NatalizumabBoxed warningApprovedBiogenAntibodyInhibitorIntegrin alpha-4/beta-1 inhibitor11
      FirategrastPhase 2GSKSmall moleculeAntagonistIntegrin alpha-4/beta-1 antagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      REAL-MS: Observational Database Study of AHSCT and MS TherapiesNatalizumab—RecruitingImperial College LondonOct 27, 2026
      Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyNatalizumabPhase 2RecruitingUniversity of Michigan Rogel Cancer CenterOct 23, 2026
      Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and SerologicNatalizumabNot applicableRecruitingUniversity Hospital, MontpellierJul 27, 2023
      A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesNatalizumab—Active, not recruitingBiogenJan 18, 2023
      Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)Natalizumab—RecruitingBiogenDec 20, 2022
      Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)NatalizumabPhase 2RecruitingQueen Mary University of LondonJun 14, 2022
      Covid-19 Vaccine Immune Response in Multiple SclerosisNatalizumab—Active, not recruitingUniversity Hospitals of North Midlands NHS TrustMar 8, 2022
      Cladribine Tablets After Treatment With Natalizumab (CLADRINA)NatalizumabPhase 4Active, not recruitingUniversity of Texas Southwestern Medical CenterNov 26, 2019

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1907599, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.